Affinity Asset Advisors, LLC holds a diversified book of 95 reported positions worth $1.7B as of Q1 2026 (disclosed May 14, 2026, a ~44-day 13F lag). This quarter Helix Acquisition Corp-CL A first appears in 13F filings (one of 4 new listings in the book), a listing rather than a purchase; they opened Enliven Therapeutics Inc and trimmed Spyre Therapeutics Inc. Their largest long position is Apogee Therapeutics Inc at 6% of the reported non-option book. They also disclosed $149.4M in put options (a bearish bet) and $81.9M in call options (bullish), shown separately below and excluded from the non-option book. Cloning the disclosed picks since 2021 would be +48% (+7.2%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 12.2 points over this window.
Growth of $10,000 cloning Affinity Asset Advisors, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~44 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
92% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Affinity Asset Advisors, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Fairmount Funds Management LLC | 8 / 80 | $1.4B |
| Venrock Adviser, LLC | 15 / 80 | $2.7B |
| Paradigm Biocapital Advisors LP | 13 / 80 | $3.6B |
| Patient Square Capital LP | 8 / 80 | $431.0M |
| Commodore Capital LP | 14 / 80 | $1.1B |
| First Turn Management, LLC | 17 / 80 | $583.5M |
| Avidity Partners Management LP | 10 / 80 | $381.7M |
| Artia Global Partners LP | 19 / 80 | $316.9M |
Ranked by the share of each fund's own book sitting in the names it shares with Affinity Asset Advisors, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Apogee Therapeutics Inc COM | $108.2M | 1.28M | 6.3% | ▲+4.0% Added · +50K sh | |
| 2 | Xenon Pharmaceuticals Inc COM | $97.4M | 1.68M | 5.7% | ▲+34% Added · +425K sh | |
| 3 | Erasca Inc COM | $86.6M | 5.35M | 5.1% | ▲+37% Added · +1.4M sh | |
| 4 | Insmed Inc COM PAR $.01 | $78.5M | 480.0K | 4.6% | ▲+6.7% Added · +30K sh | |
| 5 | Roivant Sciences Ltd SHS | $77.6M | 2.80M | 4.5% | ▲+65% Added · +1.1M sh | |
| 6 | Spyre Therapeutics Inc COM NEW | $64.5M | 1.28M | 3.8% | ▼−11% Reduced · −153K sh | |
| 7 | Centessa Pharmaceuticals PLC SPONSORED ADS | $55.6M | 1.40M | 3.3% | ▲+133% Added · +799K sh | |
| 8 | Praxis Precision Medicines I COM NEW | $54.8M | 170.0K | 3.2% | ▼−8.1% Reduced · −15K sh | |
| 9 | Anaptysbio Inc COM | $52.1M | 940.0K | 3.1% | ▲+111% Added · +495K sh | |
| 10 | Alkermes PLC SHS | $47.7M | 1.35M | 2.8% | ▲+35% Added · +350K sh | |
| 11 | Cytokinetics Inc COM NEW | $46.2M | 700.5K | 2.7% | ▼−12% Reduced · −100K sh | |
| 12 | Abivax Sa SPONSORED ADS | $45.1M | 405.0K | 2.6% | ▼−20% Reduced · −100K sh | |
| 13 | Teva Pharmaceutical Inds Ltd SPONSORED ADS | $42.2M | 1.40M | 2.5% | —Held | |
| 14 | Arcellx Inc COMMON STOCK | $41.7M | 362.8K | 2.4% | ▼−31% Reduced · −161K sh | |
| 15 | Nuvalent Inc COM | $30.7M | 300.0K | 1.8% | ▼−7.0% Reduced · −23K sh | |
| 16 | Terns Pharmaceuticals Inc COM | $29.7M | 562.6K | 1.7% | ▲+2.3% Added · +13K sh | |
| 17 | Dianthus Therapeutics Inc COM | $29.4M | 350.0K | 1.7% | ▲+204% Added · +235K sh | |
| 18 | Lexeo Therapeutics Inc COM | $29.0M | 5.05M | 1.7% | ▲+58% Added · +1.9M sh | |
| 19 | Cogent Biosciences Inc COM | $28.9M | 750.0K | 1.7% | ▲+114% Added · +400K sh | |
| 20 | Madrigal Pharmaceuticals Inc COM | $28.8M | 55.0K | 1.7% | ▲+77% Added · +24K sh | |
| 21 | Sutro Biopharma Inc COM SHS | $26.6M | 1.07M | 1.6% | ▲+43% Added · +321K sh | |
| 22 | Forte Biosciences Inc COM NEW | $26.2M | 1.01M | 1.5% | ▲+2.3% Added · +22K sh | |
| 23 | Oruka Therapeutics Inc COM | $24.5M | 499.7K | 1.4% | ▼−38% Reduced · −303K sh | |
| 24 | Trevi Therapeutics Inc COM | $23.9M | 2.00M | 1.4% | ▼−7.0% Reduced · −150K sh | |
| 25 | Ovid Therapeutics Inc COM | $23.6M | 10.64M | 1.4% | ▲+49% Added · +3.5M sh | |
| 26 | Enliven Therapeutics Inc COM | $23.0M | 586.9K | 1.3% | ▲New New position | |
| 27 | Ascendis Pharma A/s SPONSORED ADR | $21.7M | 95.0K | 1.3% | ▲+217% Added · +65K sh | |
| 28 | Mineralys Therapeutics Inc COM | $20.3M | 750.0K | 1.2% | ▲+2.7% Added · +20K sh | |
| 29 | Avalo Therapeutics Inc COM NEW | $20.0M | 1.34M | 1.2% | ▲+28% Added · +290K sh | |
| 30 | Protagonist Therapeutics Inc COM | $18.1M | 172.1K | 1.1% | —Held | |
| 31 | Celldex Therapeutics Inc New COM NEW | $15.9M | 500.0K | 0.9% | ▲+43% Added · +150K sh | |
| 32 | Zura Bio Ltd CLASS A ORD SHS | $15.3M | 2.56M | 0.9% | ▲+41% Added · +751K sh | |
| 33 | Nurix Therapeutics Inc COM | $15.0M | 967.6K | 0.9% | —Held | |
| 34 | Savara Inc COM | $13.7M | 2.51M | 0.8% | ▼−10% Reduced · −285K sh | |
| 35 | Omeros Corp NOTE 9.500% 6/1 | $13.2M | 6.53M | 0.8% | —Held | |
| 36 | Perspective Therapeutics Inc COM NEW | $13.2M | 3.16M | 0.8% | ▲11× Added · +2.9M sh | |
| 37 | Helix Acquisition Corp III USD CL A ORD SHS | $12.7M | 1.25M | 0.7% | →Listed Newly reportable | |
| 38 | Arrowhead Pharmaceuticals In COM | $12.5M | 200.0K | 0.7% | ▲+186% Added · +130K sh | |
| 39 | Damora Therapeutics Inc COM NEW | $11.7M | 450.0K | 0.7% | ▲New New position | |
| 40 | Eupraxia Pharmaceuticals Inc COM | $11.5M | 1.59M | 0.7% | ▲+430% Added · +1.3M sh | |
| 41 | Alto Neuroscience Inc COM SHS | $11.2M | 500.0K | 0.7% | ▲New New position | |
| 42 | Bridgebio Pharma Inc COM | $11.1M | 150.0K | 0.7% | ▼−53% Reduced · −170K sh | |
| 43 | Cullinan Therapeutics Inc COM | $11.1M | 781.3K | 0.7% | ▼−60% Reduced · −1.2M sh | |
| 44 | Belite Bio Inc SPONSORED ADS | $10.4M | 65.0K | 0.6% | ▲+225% Added · +45K sh | |
| 45 | Wave Life Sciences Ltd SHS | $10.2M | 1.40M | 0.6% | ▼−48% Reduced · −1.3M sh | |
| 46 | Vera Therapeutics Inc CL A | $10.1M | 250.0K | 0.6% | —Held | |
| 47 | Tyra Biosciences Inc COM | $9.9M | 257.5K | 0.6% | ▲New New position | |
| 48 | Revolution Medicines Inc COM | $9.7M | 100.0K | 0.6% | —Held | |
| 49 | Jade Biosciences Inc COM NEW | $9.0M | 640.0K | 0.5% | ▼−10% Reduced · −75K sh | |
| 50 | Travere Therapeutics Inc COM | $8.9M | 300.0K | 0.5% | —Held |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1773195/holdings"
Use Arkolith to show Affinity Asset Advisors, LLC's latest holdings, largest changes, and filing provenance.
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $130.1M | 200K |
| CALL · bullish | MODERNA INCMRNA | $40.6M | 800K |
| CALL · bullish | BRISTOL-MYERS SQUIBB COBMY | $18.2M | 300K |
| PUT · bearish | REVOLUTION MEDICINES INCRVMD | $9.7M | 100K |
| PUT · bearish | IMMUNITYBIO INCIBRX | $9.6M | 1.3M |
| CALL · bullish | NOVO-NORDISK A/S-SPONS ADRNVO | $6.4M | 175K |
| CALL · bullish | UNIQURE NVQURE | $4.9M | 300K |
| CALL · bullish | DIANTHUS THERAPEUTICS INCDNTH | $4.2M | 50K |
| CALL · bullish | CG ONCOLOGY INCCGON | $4.1M | 60K |
| CALL · bullish | CELCUITY INCCELC | $3.4M | 30K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the non-option book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 44d | 105 | $1.9B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 44d | 95 | $1.8B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 13, 2025 | 44d | 96 | $1.1B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 13, 2025 | 44d | 91 | $732.2M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 44d | 98 | $1.0B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 13, 2025 | 44d | 85 | $746.0M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 13, 2024 | 44d | 86 | $732.8M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 45d | 98 | $867.5M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 44d | 95 | $807.8M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 13, 2024 | 44d | 82 | $547.5M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 45d | 81 | $355.5M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 21, 2023 | 52d | 70 | $286.3M | 13F-HR/A |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 45d | 74 | $303.0M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 13, 2023 | 44d | 63 | $255.0M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 45d | 64 | $358.3M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 43d | 54 | $237.2M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 13, 2022 | 43d | 59 | $625.0M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 11, 2022 | 42d | 55 | $275.4M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 43d | 73 | $396.0M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 13, 2021 | 44d | 69 | $279.3M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 44d | 72 | $294.5M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 43d | 62 | $188.7M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.